Results 251 to 260 of about 1,782,190 (315)
VeGA-RX and VeGA-SCX: Controllable SMARTS-Guided Generative Transformers for Precision-Driven <i>De Novo</i> Drug Design. [PDF]
J Chem Inf ModelDelre P, Bellofatto G, Lavecchia A.
europepmc +1 more source
Which halogen to choose? Comparing the effects of chlorine and fluorine as bioisosteric substituents in drug design. [PDF]
Chem SciSummerfield CJE, Pattison G.
europepmc +1 more source
Standards for Computational Methods in Drug Design and Discovery: Simplified Guidance for Authors and Reviewers. [PDF]
Drug Des Devel TherIbrahim TM, Hussain M, Boeckler FM.
europepmc +1 more source
Assay2Mol: Large Language Model-based Drug Design Using BioAssay Context. [PDF]
Proc Conf Empir Methods Nat Lang ProcessDeng Y, Ericksen SS, Gitter A.
europepmc +1 more source
Is Mycobacterial InhA a Suitable Target for Rational Drug Design? [PDF]
ChemMedChemRizet J +7 more
europepmc +1 more source
Advancing in silico drug design with Bayesian refinement of AlphaFold models
Sen S +4 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
European Journal of Pharmacology, 2009
In this article, current knowledge of drug design is reviewed and an approach of rational drug design is presented. The process of drug development is challenging, expensive, and time consuming, although this process has been accelerated due to the development of computational tools and methodologies.
Soma Mandal
exaly +3 more sources
In this article, current knowledge of drug design is reviewed and an approach of rational drug design is presented. The process of drug development is challenging, expensive, and time consuming, although this process has been accelerated due to the development of computational tools and methodologies.
Soma Mandal
exaly +3 more sources
Emergency Medicine Clinics of North America, 2021
In recent years, there has been an emergence of numerous novel drugs. Such toxicity may occur in both adolescents and adults. This article discusses the opioid epidemic and several emerging opioids, including buprenorphine, loperamide, fentanyl, fentanyl derivatives, and others.
Michael, Levine, Frank, Lovecchio
openaire +2 more sources
In recent years, there has been an emergence of numerous novel drugs. Such toxicity may occur in both adolescents and adults. This article discusses the opioid epidemic and several emerging opioids, including buprenorphine, loperamide, fentanyl, fentanyl derivatives, and others.
Michael, Levine, Frank, Lovecchio
openaire +2 more sources
Clinical Pharmacology & Therapeutics, 2017
This “Designer Drugs 2.0” issue of Clinical Pharmacology & Therapeutics focuses on novel psychoactive substances, primarily cannabinoids and cathinones, and the repurposing of established psychoactive compounds (e.g., modafinil, psilocybin, lysergic acid diethylamide, and 3,4‐methylenedioxymethamphetamine) that simultaneously offer new ...
M A, Huestis, R F, Tyndale
openaire +2 more sources
This “Designer Drugs 2.0” issue of Clinical Pharmacology & Therapeutics focuses on novel psychoactive substances, primarily cannabinoids and cathinones, and the repurposing of established psychoactive compounds (e.g., modafinil, psilocybin, lysergic acid diethylamide, and 3,4‐methylenedioxymethamphetamine) that simultaneously offer new ...
M A, Huestis, R F, Tyndale
openaire +2 more sources
Current Pharmaceutical Design, 2003
The following review outlines the physiological outcome of VIP and VIP gene manipulations. Previously, we reviewed the various VIP receptors associated with biological functions ranging from growth regulation, sexual function, bronchodilation, vasodilation and immune interactions to neurotrophism. VIP-based drug design is discussed below.
Illana, Gozes, Sharon, Furman
openaire +2 more sources
The following review outlines the physiological outcome of VIP and VIP gene manipulations. Previously, we reviewed the various VIP receptors associated with biological functions ranging from growth regulation, sexual function, bronchodilation, vasodilation and immune interactions to neurotrophism. VIP-based drug design is discussed below.
Illana, Gozes, Sharon, Furman
openaire +2 more sources